Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zinc and prostate cancer

This article was originally published in The Tan Sheet

Executive Summary

A study finds "no statistically significant association" between zinc supplementation and prostate cancer risk, according to a letter in the Journal of the National Cancer Institute by the study authors. Ellen Chang, Karolinska Institute, Stockholm, et al., conducted a population-based case-control study among 1,499 prostate cancer patients and 1,130 control subjects, finding no increase in prostate cancer risk arising from supplemental zinc use categorized by frequency, duration or cumulative exposure. The results contradict a 2003 JNCI study that reported a greater risk of prostate cancer among users of supplemental zinc (1"The Tan Sheet" July 14, 2003, In Brief)...

A study finds "no statistically significant association" between zinc supplementation and prostate cancer risk, according to a letter in the Journal of the National Cancer Institute by the study authors. Ellen Chang, Karolinska Institute, Stockholm, et al., conducted a population-based case-control study among 1,499 prostate cancer patients and 1,130 control subjects, finding no increase in prostate cancer risk arising from supplemental zinc use categorized by frequency, duration or cumulative exposure. The results contradict a 2003 JNCI study that reported a greater risk of prostate cancer among users of supplemental zinc (1 'The Tan Sheet' July 14, 2003, In Brief)....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel